

Pressure BioSciences, Inc.

12:20 12 Jun 2019

Spotlight on Pressure BioSciences' PCT platform at major international science summit

Pressure BioSciences Inc (OTCQB:PBIO) said Wednesday that its Pressure Cycling Technology (PCT) platform received plaudits at the American Society for Mass Spectrometry (ASMS) meeting in Atlanta, boosting its potential in the biopharma market.

PCT is a patented technology that uses alternating cycles of hydrostatic pressure between ambient (14.7 pounds per square inch) and ultra-high levels (up to 45,000 psi) to safely control biomolecular interactions.

At least 15 presentations spanning cancer research, protein function, molecular biology, and biomarker discovery discussed how the PCT platform allows for a high degree of safety, speed, reproducibility, and convenience in the creation of sample preparation protocols.

READ: Pressure BioSciences shares jump after life sciences company sets up Center of Excellence at NYU lab

Roxana McCloskey, global director of sales and marketing at Pressure BioSciences, said the Barocycler 2320EXT machine can analyze under pressure up to 16 samples simultaneously, boosting the discovery of new drugs and treatments.

"We believe this could eventually lead to the routine use of the PCT platform in precision medicine, a rapidly expanding market that is expected to reach \$217 billion by 2028 according to BIS Research," said McCloskey.

Cancer Research

Nine presentations focused on the importance of the PCT platform in studying cancers. Of these, three described the development and use of a novel, streamlined, sample preparation protocol and system featuring the company's Barocycler 2320EXT instrument and MicroTubes as the link between two widely used techniques: laser microdissection and mass spectrometry.

Precise small sections of cells are cut from suspected tumor tissue slices while being viewed under a microscope. Once cut from the biopsy tissue, the slices of interest fall directly into PBI's MicroTubes, and are processed by the PCT platform and are then analyzed by mass spectrometry. The PCT platform is able to accelerate and strengthen protein analysis, improve cancer characterization, and provide clinically relevant information for diagnosis.

Researchers from China and Australia reported on advancements in their cancer diagnostic programs. These large studies of thousands of cancer samples rely critically on the PCT platform to rapidly and reproducibly extract proteins from tumor tissues for analysis by mass spectrometry.


Biomarker discovery

Several presentations reported results from studies that used the PCT platform for basic research and discovery of unique cancer biomarkers. Discovery of new biomarkers for early diagnosis, cancer subtyping, progression, and underlying pathway dysfunction is vital to help improve clinical outcomes.

Price: 1.545

Market Cap: \$5.52 m

1 Year Share Price Graph



October 2019 April 2020 October 2020

Share Information

Code: PBIO

Listing: OTCQB

52 week	High	Low
	4.49	0.6006

Sector: Medical technology & services

Website: www.pressurebiosciences.com

Company Synopsis:

Pressure BioSciences Inc. (OTCQB: PBIO): A leader in the sale of innovative, broadly enabling, pressure-based instruments and consumables for the worldwide life sciences industry.

action@proactiveinvestors.com

In addition to cancer biomarker discovery, a presentation reported the use of the PCT platform to help reveal unique biomarkers due to exposure to chemicals in the environment, such as benzene.

This is the second report which highlights using Pressure Bioscience technology to monitor the effects of environmental pollutants.

Protein and molecular biology

Studies also highlighted how the high-pressure PCT system was used to accelerate enzymatic reactions for molecular biology and other applications, and for muscle tissue studies.

"We are thrilled with both the number and caliber of presentations made at the annual ASMS conference highlighting the advantages of the PCT platform," said Pressure BioSciences CEO Richard T Schumacher.

Researchers from labs in Johns Hopkins University, Fred Hutchinson Cancer Center, John P Murtha Cancer Center, the Inova Schar Cancer Institute, Westlake University (China), the Children's Medical Research Institute, PPD Madison, and Pfizer discussed the importance of the PCT platform.

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Pressure BioSciences, Inc. named herein, including the promotion by the Company of Pressure BioSciences, Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).